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Abstract  
Chronic cancer pain remains prevalent and severe for many patients, particularly in those 
with advanced disease. The effectiveness of analgesic/adjuvant drug treatments in routine 
practice has changed little in the last 30 years. To address these issues herein, we have 
developed sustained-release poly(lactic-co-glycolic acid) (PLGA) microparticles of 
hydromorphone for intrathecal injection aimed at producing prolonged periods of satisfactory 
analgesia in patients, as a novel strategy for alleviation of intractable cancer-related pain. 
These hydromorphone-loaded microparticles were produced successfully using organic 
solvent free supercritical fluid polymer encapsulation. Drug loading at 9.2 % and 
encapsulation efficacy at 92 % were achieved for particles in the desired size range (20-
45µm) with sustained release over a 5 week period in vitro.  
Keywords 
Chronic cancer pain; Intrathecal injection; Poly(lactic-co-glycolic acid) (PLGA); 
microparticles;  Satisfactory analgesia, Supercritical CO2.  
Introduction  
One of the most common symptoms caused by cancer is chronic pain, which is the most 
feared symptom by patients throughout the course of the disease 1. The pain may be 
exacerbated by treatment with chemotherapy drugs or by radiation resulting in poorly 
alleviated pain complicated by a neuropathic component 2,3. Despite administration of 
escalating doses of strong opioid analgesics such as morphine, up to 30% of patients do not 
achieve satisfactory pain relief 4. The effectiveness of treatment in the clinical setting has 
changed little in the last 30 years 1,5. Hence, new strategies are needed to address this issue of 
intractable cancer-related pain. One such strategy is the development of sustained-release 
biodegradable analgesic-containing microparticles for intrathecal injection as a means to 
produce continuous analgesia for several weeks in patients suffering from severe chronic 
cancer-related pain 6. Poly(lactic-co-glycolic acid) (PLGA) based hydromorphone-loaded 
microparticles were prepared by a water-in-oil-in-water (w/o/w) double-emulsion method 
because of the safety, biodegradability, and successful application of PLGA in the clinical 
setting 7. However, micro-encapsulation of drug payloads using conventional w/o/w emulsion 
methods resulted in particles with poor hydromorphone loading at 1.6% 6. Additionally, large 
quantities of toxic organic solvents and surfactants/emulsifiers were also used, potentially 
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leading to unacceptable levels of residual impurities in the microparticles necessitating 
further purification steps 8. However, the use of supercritical fluids such as supercritical CO2 
(scCO2) provides a ‘clean’ and effective alternative to traditional methods of drug and 
polymer processing. In particular, scCO2 has a number of unique properties that make it 
possible to produce sustained-release drug-loaded microparticles without using toxic organic 
solvents or elevated temperatures 9,10.  
 
In the present study, we produced sustained-release microparticles containing the strong 
opioid analgesic, hydromorphone, for the first time using organic solvent free supercritical 
fluid polymer encapsulation (CriticalMix) technology. Hydromorphone drug loading of these 
microparticles was 9.2% which is very close to our target loading of 10% for intrathecal 
injection. The particle sizes were the designed size range (<45µm). Importantly, 
hydromorphone release was sustained over a 5 week period in vitro.  
1 Materials and Methods  
1.1 Preparation of hydromorphone-loaded polymeric microparticles  
Hydromorphone HCl (Sigma Aldrich) was converted to the corresponding free base form by 
adjusting the pH to ~10 using 2 M NaOH added dropwise 6. The scCO2 microparticle 
manufacturing (CriticalMix) process was optimised according to Whitaker et al. 11.  Briefly, 
the PLGA50:50DLG1.5E (Poly(lactic-co-glycolic acid) (PLGA) biodegradable polymer 
(50:50); ester end-capped, inherent viscosity (0.1-0.2 dl/g) and ~Tg 28°C measured by 
Differential scanning calorimetry (DSC), custom made by Evonik Health care) and 
hydromorphone at a ratio of 90 to 10 were loaded into a pressure vessel, pressurised with 
CO2 (pharmaceutical grade CO2 was from BOC Special Gasses, UK) and heated to 40°C at a 
pressure of 14 MPa for reaching the supercritical point and ensures that the polymer is 
fluidised 12. Once temperature was reached the mixture of CO2/polymer/drug inside the 
vessel was mixed using mechanical stirring. Liquefaction of the polymer by the scCO2 
facilitated drug incorporation into the polymer. About half to one hour later heating was 
stopped and the polymer-hydromorphone-scCO2 allowed to cool to below 25°C before the 
CO2 was slowly vented, depressurised through a nozzle with a 0.6 mm orifice. The polymer 
solidified to entrap hydromorphone and form microparticles containing hydromorphone. The 
temperature was reduced to 25°C before unloading to ensure that the drug remained in the 
polymer and that drug loss was minimized during CO2 venting.  Microparticles were 
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collected and grounded with a pestle and mortar, and sieved through a 45 micron sieve. The 
final product was stored refrigerated at a mean (±SD) temperature of 5(±3)°C and protected 
from light in a desiccator. 
1.2 Characterizations of drug-loaded PLGA microparticles  
Drug incorporation efficiency. Triplicate ~5mg samples were weighed and dissolved in 2ml 
aliquots of acetonitrile. The hydromorphone concentrations were quantified using HPLC with 
UV detection at 280nm. Drug incorporation efficiency, expressed as actual drug loading (% 
w/w) and encapsulation efficiency (EE % w/w) were calculated using equations (1-2) 
respectively. The individual values for three replicate determinations and their mean (±SD) 
values are reported. 
Eq. (1) Drug loading (%) = 100 × mass of drug in microparticles/ mass of microparticles  
Eq. (2) EE (%) = 100 × mass of drug in microparticles/ mass of drug in microparticles 
theoretically  
In vitro drug release. Triplicate samples (~10mg) of hydromorphone-loaded polymeric 
microparticles (n=3) were suspended in 1 mL of PBS and transferred to dialysis tubes. Each 
dialysis tube was sealed, placed into a capped container containing 20ml PBS, and then 
placed into an incubator maintained at 37.5°C and shaken horizontally at an oscillating 
frequency of 120 min-1. Timepoints were taken at 3 and 24 h, 3, 7, 14, 21 and 28 days. At 
each timepoint a 1 ml aliquot of buffer was taken for analysis, and replaced with fresh buffer. 
At each time point, the 1 ml samples (n=3) were analysed by HPLC and the cumulative 
release determined.  
Morphology and Particle Size. The sustained-release hydromorphone-loaded PLGA 
microparticles were sputter coated with platinum using an Auto Smart Coater (JFC-1300, 
JEOL Ltd. Tokyo, Japan) and then examined using a scanning electron microscope (Jeol 
IT300, JEOL Ltd. Tokyo, Japan) to determine particle shape and surface morphology.  
2 Results and Discussion  
Sustained-release hydromorphone-loaded PLGA microparticles were successfully prepared 
for the first time using organic solvent free supercritical fluid polymer encapsulation 
(CriticalMix) technology by incorporation of hydromorphone into PLGA50:50DLG1.5E at a 
ratio of 10 to 90 respectively, followed by milling. Importantly, hydromorphone was stable 
under the scCO2 processing conditions. Hydromorphone loading at 9.2(±0.2)% was achieved 
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with EE at 92% with these parameters being 4-5 times higher than our previous work using a 
w/o/w emulsion method (drug loading of 1.6% and EE of 26%) 6 (Table 1). Additionally, the 
microparticle size was mainly in the range of 20-45 µm after Grinding (Figure 1) which was 
within our designed size range of 20-60 µm 6. Regarding release, there was an initial 20.7% 
burst release in the first 24 hours that was followed by a slower zero-order release phase 
lasting for up to ~35-days (Figure 2). Grinding and sieving should have little effect on burst 
release as shown by the in vitro release profile in Figure 2. There was no clear difference in 
the morphology of sustained-release hydromorphone-loaded microparticles (Figure 1A) and 
drug free microparticles (Figure 1B). Both microparticles were random in shape without 
aggregation even after 9 months in storage at 2-8°C. Our findings demonstrate that scCO2 
encapsulation technology has potential as a drug delivery platform for  small molecules such 
as hydromorphone (as the free base) with the polymeric particles being free from organic 
solvent residues and surfactants after processing 13.  
Our data extend work by others whereby large protein molecules such as human growth 
hormone (hGH, a 22 kDa protein) 14 and vaccines of tetanus toxoid (TT) 15 were successfully 
encapsulated into PLGA/poly(lactic acid) (PLA) and PLA particles respectively using the 
scCO2 CriticalMix process. These results together with our data herein demonstrate the 
potential of the scCO2 CriticalMix process for preparation of clean, organic-solvent free, 
particles loaded with either large and small molecules. 
Importantly, our simple CriticalMix process to produce hydromorphone-loaded 
microparticles extends previous work by Cabezas et al. 16-18 who used a one-step scCO2 
procedure to produce either indomethacin or 5-fluorouracil impregnated PLGA porous 
scaffolds. In the present study, the temperature of 40°C was needed to be above the critical 
point of 31.1°C and it ensured that the polymer was fluidised12. Temperature also has some 
effect on drug loading and encapsulation.  If the drug is soluble in the CO2 then raising the 
temperature would lead to higher solubility in CO2 and lower the loading. On the other hand, 
raising the temperature will also reduce the viscosity of the CO2 plasticised polymer. This can 
enhance mixing and hence could increase loading.  So a sensible balance point has to be 
achieved. The scCO2 mixing process yielded a monolithic material that was of the order of 
centimetres cubed – it filled the high pressure vessel.  This material was then controllably 
milled to yield the particles for release analysis. It is clear from our collective findings that 
payload solubility in scCO2 as well as CO2 sorption and swelling of the polymer vary with 
temperature, pressure, contact time, stirring rate of the scCO2/polymer/drug solution as well 
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as depressurization conditions including CO2 venting rate and venting temperature. By 
systematically varying these parameters, the desired loading and release profile can be 
optimised for each drug of interest incorporated into PLGA-particles or PLGA porous 
scaffolds.  
3 Conclusion 
Hydromorphone encapsulated PLGA microparticles were successfully prepared using organic 
solvent free supercritical fluid polymer encapsulation technology followed by milling. The 
~35-day sustained-release profile was achieved using PLGA50:50DLG1.5E with 
hydromorphone loading at 9.2% and EE of 92% in vitro in the absence of organic solvents or 
surfactants.  Our data show that supercritical fluid polymer encapsulation technology has 
potential for producing microparticles containing analgesic drugs for sustained release over 
several weeks for potential administration by the intrathecal route, as a means to improve the 
management of otherwise poorly-alleviated severe cancer-related pain.  
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Figure Legends:  
Figure 1. Microparticle size and morphology.  
There is no clear difference between hydromorphone-loaded PLGA microparticles (A) and 
drug free PLGA microparticles (B) after 9 months of storage at 2-8°C. The particles are 
similar in shape and size as freshly prepared particles.   
 
 
Figure 2. Mean (±SEM) in vitro release profile of hydromorphone microencapsulated in 
PLGA5050-1.5E (n=3) with particles prepared using a scCO2 method. Sustained-release 
PLGA5050-1.5E based hydromorphone-loaded microparticles released their payload over an 
approximately 35-day period in vitro.  
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Table 1. Physical characteristics of hydromorphone-loaded PLGA microparticles 
 
 
 
 
 
 
 
 
 
 
 
DCM, dichloromethane; EE, encapsulation efficiency; IV, inherent viscosity; PLGA, 
poly(lactic-co-glycolic acid); PVA, poly (vinyl alcohol); scCO2, supercritical CO2 
Parameters scCO2 method Emulsion method 
Polymers  
IV (dL/g) 
PLGA5050 ester end-
capped  
IV (0.1-0.2) 
PLGA5050 acid 
end-capped  
IV (0.55-0.75) 
Theoretical drug loading 
(%) 
10 
 
6-12 
 
Drug loading (%) 9.2 1.6 
EE (%) 92 26 
Size (µm)  20-45  20-60 
Period of in vitro release ~35days ~28days 
Solvent  
& surfactants  
None  
 
DCM, PVA 
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